Loading stock data…
AZN
$183.43+1.88 (+1.04%)
After Hours$183.43+0.00 (+0.00%)· Last close Jun 9
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AstraZeneca PLC in the Healthcare sector is trading at $183.43. Wall Street consensus targets $224.49 (10 analysts), implying a +22.4% move over the next 12 months. The stock is currently 14% below its 52-week high of $212.71, remaining 1.5% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +22.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$183.43
Potential Downside
0%
Whystock Fair Value$183.43
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$224.49+22.4%
Range$184.00 – $245.00
Fundamentals
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
1.73%
ROE
Elite ROE. Management converts capital into profit efficiently.
21.95%
Volume
Today's trading volume
1.80M
Recent News
Prediction: Eli Lilly Will Trade at This Price in a Year
Eli Lilly (NYSE:LLY) is finally acting like a trillion-dollar drugmaker again. After a brutal stretch in late 2025 and a wobbly start to this year, the stock punched through fresh 52-week highs on retatrutide Phase 3 data that analysts call potentially first-line for obesity. The stock trades at $1,149.15 with a one-year gain of 50.31%, ... Prediction: Eli Lilly Will Trade at This Price in a Year
JNJ and AZN Face Patent Headwinds: Which Stock Looks Stronger Now?
J&J's diversified healthcare business and growth outlook help it stand out against AstraZeneca despite patent and legal challenges.
GSK Buys Nuvalent for $10.6 Billion in Major Cancer Push
(Bloomberg) -- GSK Plc agreed to buy Nuvalent Inc. for $10.6 billion, securing a US biotech firm developing treatments for lung cancer as part of the British pharmaceutical company’s effort to rebuild its oncology franchise.Most Read from BloombergHouse Republican Says Hegseth’s D-Day Remarks ‘Inappropriate’Stocks Hit by Chipmaker Rout Amid US-Iran Jitters: Markets WrapOpenAI Joins a Massive AI IPO Pipeline Now Worth $3.6 TrillionLA Mayor Race Flips as Socialist Beats Reality TV Star PrattTrump’
AstraZeneca’s GLP-1 Pill Clears Early Hurdle in Diabetes, Obesity Tests
AstraZeneca’s experimental GLP-1 pill cut body weight by nearly 12% in obese patients over 36 weeks and reduced A1C, a metric for blood-sugar levels, by 1.9 percentage points on average in diabetic patients, according to Phase 2 trial results presented Monday at the American Diabetes Association’s annual conference. The results, which were simultaneously published in The Lancet, are part of a broader push by the British drugmaker to target diabetes, heart disease, kidney failure and liver disease—not cosmetic weight loss—in a bet that treating specific conditions will keep insurers paying as coverage for weight-loss drugs tightens.
LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZeneca’s Therapies In Diabetes Trials
Lilly’s Foundayo outperformed existing treatments on blood sugar control and weight loss in type 2 diabetes patients in three late-stage trials.